Researchers have found in a new study that patients with anaphylaxis and cardiovascular disease experienced a 32% longer hospital stay. In the study, all 115,395 anaphylaxis hospitalizations were analyzed, and out of them, 60.9% of patients had pre-existing cardiovascular disease. It was revealed that overall, outcomes were worse in anaphylaxis patients with underlying cardiovascular conditions. The findings of the study were reported at a major allergy and immunology meeting.These findings are published in the Journal of Allergy and Clinical Immunology in February 2026.Anaphylaxis is defined as a rapid-onset, systemic hypersensitivity reaction necessitating immediate intervention, yet the prognostic impact of pre-existing cardiovascular disease (CVD) on these patients has remained a critically underrecognized area in medicine. To address this clinical gap, Dr. Diala Merheb and a team of clinical researchers from the University of Kansas (KU) School of Medicine evaluated the association between various forms of heart disease and in-hospital outcomes among patients across the United States.The study utilized a retrospective design by analyzing the National Inpatient Sample (NIS) data from 2016 to 2022 to identify a massive cohort of 115,395 weighted adult hospitalizations where anaphylaxis was the primary diagnosis. By excluding pediatric populations and employing multivariable regression models adjusted for age, sex, and the Charlson Comorbidity Index (CCI), the researchers evaluated primary endpoints such as in-hospital mortality and length of stay (LOS), while secondary outcomes focused on acute systemic complications.Key Clinical Findings of the Study Includes:Elevated Mortality: Study identifies that individuals with pre-existing heart conditions face nearly twofold higher mortality compared to those without such comorbidities (adjusted odds ratio [aOR] 1.97, 95% CI 1.60–2.42). Arrhythmia Severity: Evidence indicates that among various cardiovascular subtypes, arrhythmias are the most lethal, associated with a 5.19 times higher risk of in-hospital death. Organ Complications: Research highlights that these patients face a 3.85-fold increase in myocardial infarction (MI) odds and a 27% higher likelihood of developing acute kidney injury (AKI). Respiratory Impact: Data shows a significantly higher pulmonary burden, with a 33% increased risk of respiratory failure (aOR 1.33) and a 41% higher risk of experiencing bronchospasm (aOR 1.41). Prolonged Recovery: Findings demonstrate that the presence of cardiovascular disease is associated with a 32% longer duration of hospitalization.The results suggest that with 60.9% of anaphylaxis hospitalizations involving patients with pre-existing cardiovascular disease, there is a clear and statistically significant link between heart health and the likelihood of surviving a severe allergic event. Specifically, the data confirms that these patients suffer from significantly increased rates of both in-hospital mortality and systemic organ dysfunction.Given the severe impact of these comorbidities, clinicians might consider the implementation of integrated cardiovascular risk assessments and multidisciplinary care strategies to better manage severe allergic reactions in high-risk populations.While the analysis provides vital insights, further investigations distinguishing between various allergic triggers may help researchers understand specific morbidity patterns and potentially modify the medical management of cardiovascular disease for patients who have experienced life-threatening reactions.ReferenceMerheb D, Odai R, Nguyen T, Gierer S. Impact of Cardiovascular Disease on Morbidity and Mortality in Patients Hospitalized for Anaphylaxis. J Allergy Clin Immunol.